Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Living Cell Technologies Ltd is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing, and commercializing regenerative treatments that restore function using naturally occurring cells. Its lead product, NTCELL, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Melbourne, VIC, 3000, Australia